 Shares of Calithera Biosciences Inc. CALA, -0.68 jumped 14.6 in premarket trading on Monday after the company said it received a Fast Track designation for its experimental treatment for non-small cell lung cancer. The drug is currently being tested in Phase 2 clinical trial. 